mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics

Dec 11, 2025Cancer innovation

mRNA Cancer Vaccines: From Pandemic Use to Personalized Cancer Treatments

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

More than 150 trials have demonstrated the effectiveness of mRNA vaccines in cancer treatment, particularly in melanoma.

Advancements in nucleotide modification and delivery systems have improved the stability and immune response of mRNA vaccines.
Individualized vaccines have shown response rates greater than 50% in certain patient groups.
Shared-antigen vaccines are being developed for cancers with high incidence.
Challenges include overcoming immunosuppressive tumor environments and managing systemic toxicities.
Future directions focus on self-amplifying mRNA constructs and integrating multi-omics for enhanced vaccine development.

AI simplified

The groundbreaking success of messenger RNA (mRNA) vaccines during the COVID-19 pandemic has significantly accelerated their application in oncology. This review comprehensively synthesizes the recent advancements in mRNA cancer vaccine development, emphasizing three critical domains: mechanistic innovations, clinical translation, and ongoing challenges. Technologically, advancements in nucleotide modification, (LNP) delivery systems, and AI-driven selection have significantly improved vaccine stability, immunogenicity, and personalization. Clinically, more than 150 trials have demonstrated the synergistic efficacy of mRNA vaccines (e.g., mRNA-4157/V940, BNT122) in combination with immune checkpoint inhibitors (ICIs), particularly in melanoma, with Phase III trials currently underway. Individualized neoantigen vaccines targeting patient-specific mutations have shown unprecedented response rates (> 50% in certain cohorts), while shared-antigen vaccines are progressing for high-incidence cancers. However, several critical challenges remain: (1) overcoming immunosuppressive tumor microenvironments (TME), (2) addressing systemic toxicities and LNP-related limitations, (3) scaling up cost-effective personalized manufacturing, and (4) optimizing targeted delivery. Future research directions encompass self-amplifying mRNA constructs, novel biomaterial vectors, neoadjuvant applications, and multi-omics integration for next-generation vaccine development. With rapid industrialization and evolving regulatory frameworks, mRNA vaccines are well-positioned to revolutionize precision cancer immunotherapy despite persistent translational barriers.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief